Donate For Public and Patients Store Search

F126 - The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients

Monday, March 4; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Evaluate and manage melanocytic lesions in the pregnant patient. 1. Develop treatment plans for pregnant patients with common dermatologic diagnoses.
  • Recognize and treat specific dermatoses of pregnancy.

Description

Dermatologists face multiple challenges when evaluating and treating the pregnant patient. Treatment of acne and psoriasis is difficult; risks to the fetus limit the number of evidence-based studies concerning drug therapy. Concerning melanocytic lesions, do nevi change during pregnancy, and if melanoma is diagnosed, is there a poor prognosis? Infections and infestation may present a risk for mother and fetus, and treatment options may be limited. Several dermatoses are specific for pregnancy; early recognition and management may be important to prevent adverse effects on the fetus. This forum will review these topics and provide therapeutic recommendations.

Disclosures

  • Driscoll, Marcia S., MD: UpToDate, Inc – O(H);
  • Grant-Kels, Jane Margaret, MD: no financial relationships exist with commercial interests.
  • Keri, Jonette Elizabeth, MD, PhD: Dermira – A(H); Hoffman-La Roche Ltd. – C(Fees); Ortho Dermatologics – A(H); Pierre Fabre Dermatologie – A(H); Sonoma Pharmaceuticals – A(NC); Sun Pharmaceutical Industries Ltd. – A(H);
  • Pomeranz, Miriam Keltz, MD: Procter & Gamble Company – A(Fees); UpToDate, Inc – O(IP);
  • Schlosser, Bethanee Jean, MD, PhD: Beiersdorf, Inc. – A(H); Decision Support in Medicine, LLC – O(H); UpToDate, Inc – O(H);
  • Strober, Bruce Elliot, MD, PhD: AbbVie – A(H), C(H), I(NC), O(NC); Affibody – C(Fees); Almirall – C(H); Amgen – C(H), I(NC); Arena Pharmaceuticals – C(Fees); Boehringer Ingelheim – C(H), I(NC); Bristol-Myers Squibb – A(H), C(Fees); Celgene Corporation – A(H), C(H), I(NC); Dermavant Sciences, Inc. – C(Fees); Dermira – A(H), C(H); Eli Lilly and Company – A(H), C(H), I(NC); Galderma Research & Development, LLC – I(NC); GlaxoSmithKline – C(H); Janssen-Ortho Inc. – A(H), C(H), I(NC), O(NC); Leo Pharma Inc – C(H); Meiji Seika Pharma Co., Ltd – C(Fees); Menlo Therapeutics – C(H); Merck & Co., Inc – I(NC); Novartis Pharmaceuticals Corp. – A(H), C(H); Ortho Dermatologics – C(H); Pfizer Inc. – A(H), C(H), I(NC); Sanofi/Regeneron – A(H), C(H); Sun Pharmaceutical Industries Ltd. – A(H), C(H), I(NC); UCB – A(H), C(Fees);
Schedule
Monday, March 4
1:00 PM
Dr. Driscoll / Introduction
1:10 PM
Dr. Keri / Treatment of Acne in the Pregnant Patient
1:30 PM
Dr. Grant-Kels / Evaluation and Management of Nevi and Melanoma in the Pregnant Patient
1:50 PM
Dr. Pomeranz / Specific Dermatoses of Pregnancy
2:10 PM
Dr. Schlosser / Treatment of infections and Infestation in the Pregnant Patient
2:30 PM
Dr. Strober / Treatment of Psoriasis in the Pregnant Patient
2:50 PM
All faculty / Questions and Discussion
Event Details
  • Date
    Monday, March 4
  • Time
    1:00 PM - 3:00 PM
  • Location
    Room 102B
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Marcia S. Driscoll, MD, FAAD
Speakers
  • Bethanee Jean Schlosser, MD, PhD, FAAD - Handout
  • Bruce Elliot Strober, MD, PhD, FAAD
  • Jane Margaret Grant-Kels, MD, FAAD - Handout
  • Jonette Elizabeth Keri, MD, PhD, FAAD
  • Miriam Keltz Pomeranz, MD, FAAD - Handout